IL-6受体拮抗剂治疗心肌梗死后室性心律失常患者的临床效果<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2025.06.001

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1283 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical effect of interleukin-6 (IL-6) receptor antagonist in the treatment of patients with ventricular arrhythmia after myocardial infarction.【Methods】A total of 100 patients with ventricular arrhythmia after myocardial infarction treated in our hospital from June 2022 to June 2024 were selected and divided into the observation group (treated with IL-6 receptor antagonist tocilizumab injection) and the control group (treated with conventional succinate metoprolol sustained-release tablets) according to different treatment methods, with 50 cases in each group. The total treatment efficiency, total satisfaction, quality of life, cardiac function indexes, and inflammatory factor levels were compared between the two groups. 【Results】The total treatment efficiency, satisfaction, and quality of life scores of the observation group were significantly higher than those of the control group (P<0.05); the cardiac function indexes of the observation group were better than those of the control group (P<0.05); the level of matrix metalloproteinase-9 (MMP-9) in the observation group was higher than that in the control group, while the levels of tumor necrosis factor-α (TNF-α), IL-6, and high-sensitivity C-reactive protein (hs-CRP) were lower than those in the control group, and the differences were statistically significant (P<0.05). 【Conclusion】The treatment of patients with ventricular arrhythmia after myocardial infarction with the IL-6 receptor antagonist tocilizumab injection has a significant effect, which can improve patient satisfaction, quality of life and cardiac function, and reduce the levels of inflammatory factors.

Key words： Myocardial Infarction Receptors, Interleukin-6 Arrhythmias, Cardiac Treatment Outcome

Received: 02 May 2025

PACS:

R542.22

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Suli
	ZHENG Hui
	LI Yao

Cite this article:

GAO Suli,ZHENG Hui,LI Yao. Clinical Effect of IL-6 Receptor Antagonist in the Treatment of Patients with Ventricular Arrhythmia after Myocardial Infarction[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 913-915.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.06.001 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I6/913

[1] 邱琴芳,彭晨,李泽衍,等.IL-6受体拮抗剂改善心肌梗死后室性心律失常的作用及机制初探[J].中华心血管病杂志, 2024, 52(7):791-797.
[2] 张书翔,吕海科,殷荣磊,等.重组组织型纤溶酶原激活剂治疗心肌梗死合并室性心律失常的效果观察[J].中国药物滥用防治杂志, 2024, 30(6):1057-1060.
[3] 李威,于怡驰,李毅刚.《2022年欧洲心脏病学会室性心律失常患者管理和心源性猝死预防指南》解读[J].心电与循环, 2022, 41(5):413-420.
[4] 中华医学会心血管病学分会.急性ST段抬高型心肌梗死基层诊疗指南(2024年)[J].中华全科医师杂志,2024,23(3):1-18.
[5] 高倩雯,肖钰洁,王羽维,等.IL-6加重蟾酥注射液潜在性心律失常作用[J].中国药理学通报, 2022, 38(5):712-718.
[6] 王敏燕,季俭,郝晓娇.血清NRF2和FGF21水平与ST段抬高型心肌梗死患者PCI术后恶性心律失常的相关性[J].医学研究与战创伤救治, 2023,38(7):755-759.
[7] 张卫丰,马海龙,张金玲.PCSK9抑制剂对ST段抬高型急性心肌梗死PCI后炎症水平和心室重构的影响[J].实用医学杂志, 2024, 40(15):2142-2147.
[8] 李莹莹,姚晓利,郑瑞利,等.血清miR-31,IL-22联合检测在儿童病毒性心肌炎诊断及预后评估中的价值[J].分子诊断与治疗杂志, 2024, 16(2):286-290.
[9] 王丽杰,韩丹宁.替格瑞洛治疗急性ST段抬高型心肌梗死患者的近期抗血小板疗效及不良反应发生情况[J].医学临床研究,2023,40(5):699-702.
[10] 张大伟,陈蓉.尼可地尔对行急诊冠状动脉介入治疗的急性ST段抬高型心肌梗死患者心功能、肾功能的影响[J].医学临床研究,2025,42(1):64-67.
[11] 黄攀洁,何爱娣,陈海燕.脑心通胶囊联合美托洛尔治疗冠心病心律失常疗效观察及对炎性因子的影响[J].新中医, 2023, 55(21):24-28.
[12] 井旭东,王芬.三参救心汤联合稳心颗粒对心律失常患者的效果及对炎性因子的影响[J].心血管病防治知识(学术版), 2023, 13(6):23-26.